Fingers crossed. 188 could become my favourite number

It certainly looks encouraging. - Not to pee on the parade but that is not even final endpoint data. The trial - https://clinicaltrials.gov/ct2/show/NCT03283826 - is 97 people and Phase 1 so just testing for safety. Most biotech companies are a VC funded as it is a high (financial) risk high reward game. Any crumbs of positivity are seized upon to show the investors why they need to keep ploughing money in. - If it turns out as a 'good thing' and fingers crossed that it does the firm will either be bought in whole or sell the rights to the product to a large pharma company with the financial and marketing muscle to bring it to market. - This trial ends earliest Set 2022. Then Phase 2 trials to show efficacy and if so then expanded big numbers high cost phase 3 trials before getting a license. - I'd be keeping an eye on things and be making it very clear to the nearest clinical trial centre to you that the moment it goes to a Phase 2 trial and assuming they are involved then you'd like to get signed up. - Time to market from now if everything works out perfectly and they get accelerated licensing is c. 2028.